Skip to main content
Home > BioCentury on BioBusiness > Strategy

Chronological Index of : Strategy

 Current Issue
  • Guest Commentary: Paying for cures

    How payers, companies can evaluate the value of new drugs

    A Guest Commentary proposes a framework to help evaluate the value of drugs and define financing options to ensure access.

    Published on 10/20/2014
  • Table: Avalere's five Ps

    Paying for cures Avalere's five Ps The Five Ps tie the clinical facets of new innovations to how they may impact specific payer markets in the U.S. to identify specific solutions that balance patient access with …

    Published on 10/20/2014
  • Box: Pruned by setbacks

    Streamlining Takeda's Profit Story Pruned by setbacks Takeda Pharmaceutical Co. Ltd. has experienced several recent setbacks for late-stage compounds and new launches. In December 2013, the company discontinued …

    Published on 10/13/2014
  • Box: Streamlining operations

    Streamlining Takeda's Profit Story Streamlining operations Takeda Pharmaceutical Co. Ltd. said the goal of the commercial and R&D reorganization announced last month is to make its operations more agile and to allow…

    Published on 10/13/2014
  • Figure: Takeda chronicles

    Streamlining Takeda's Profit Story Takeda chronicles Shares of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) have fallen 45% from a peak of ¥8,400 in February 2007 to ¥4,587 last Friday. The decline started when …

    Published on 10/13/2014
  • Figure: The bottom line

    Streamlining Takeda's Profit Story The bottom line While revenues for Takeda Pharmaceutical Co. Ltd. (Tokyo: 4502) have increased by 4% a year since the financial crisis in 2008-09, the pharma's EPS has declined an …

    Published on 10/13/2014
  • Table: Takeda comps

    Streamlining Takeda's Profit Story Takeda comps Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) has reported steady cost increases on an absolute basis and as a percentage of revenues since FY04, just before starting a …

    Published on 10/13/2014
  • Streamlining Takeda's Profit Story

    Takeda needs to execute on cost-cutting, pipeline to meet EPS expectations

    After a decade of acquisitions, Takeda is focused on getting costs in line with global peers and meeting expectations for EPS expansion.

    Published on 10/13/2014
  • Guest Commentary: Price cuts in HCV

    Guest Commentary: Why HCV therapy costs could start dropping fast

    A Guest Commentary predicts HCV prices will fall, and that the forces driving economic change in HCV will do so in other categories.

    Published on 10/6/2014
  • Weighing in on obesity

    How Contrave and liraglutide could succeed in obesity

    The newest obesity drugs will have the weight of pharma companies behind them in the key cardiometabolic markets required for success.

    Published on 9/22/2014
  • Table: Obesity Runway

    Weighing in on obesity Obesity runway If Orexigen Therapeutics Inc. (NASDAQ:OREX), Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Novo Nordisk A/S (CSE:NVO; NYSE:NVO) are successful in building physician awareness …

    Published on 9/22/2014
  • Cost and quality: Box: CMS bundles up

    Cancer: Cost and quality CMS bundles up CMS has signaled an interest in a bundled model for cancer reimbursement that would include physician services plus infused and outpatient drugs. The Medicare agency would not…

    Published on 9/15/2014
  • Cost and quality: Box: WellPoint's pathway

    Cancer: Cost and quality WellPoint's pathway WellPoint Inc. is piloting a treatment pathways program that dictates what drugs should be used based on tumor type and stage of disease. Clinicians who follow the …

    Published on 9/15/2014
  • Cancer: Cost and quality

    How cancer reimbursement reform could boost or inhibit drug use

    Payer reforms of cancer care may result in more drug use, depending on how the schemes balance cost-effectiveness and quality outcomes.

    Published on 9/15/2014
  • PI(3)King AbbVie

    How AbbVie, Infinity plan to make the most of duvelisib's best-in-class potential

    In one of the biggest recent cancer licensing deals, Infinity picks AbbVie to carve out a niche for duvelisib in hematologic cancers.

    Published on 9/8/2014
  • Parsing Roche's IPF bet

    How Roche can use mortality data, new indications to create Esbriet blockbuster

    Roche's ROI on Esbriet hinges on mortality data to improve uptake and reimbursement, pricing power in the U.S. and label expansions.

    Published on 9/8/2014
  • Table: On deck in IPF

    Parsing Roche's IPF bet On deck in IPF At least 16 compounds are in clinical development to treat idiopathic pulmonary fibrosis (IPF), with at least eight in Phase II testing. As the Phase III trials for both …

    Published on 9/8/2014
  • Table: Big upfronts

    PI(3)King AbbVie Big upfronts Since 2009, at least six licensing deals for clinical-stage cancer programs had upfront payments of $100 million or more. The $275 million up front in last week's deal between Infinity …

    Published on 9/8/2014
  • Back to School Issue: Paying the piper

    22nd BioCentury Back to School Issue: Time to try new pricing schemes

    As the drumbeat for cost-based pricing grows louder, the 22nd Back to School essay says industry must experiment with new pricing models in which the cost of a given treatment is based on the patient-defined value of …

    Published on 9/1/2014
  • Box: Best price barrier

    Paying the piper Best price barrier The Medicaid best price rule for outpatient drugs is cited as a barrier to implementing new pricing models in the U.S. Companies that want an outpatient drug to be covered by …

    Published on 9/1/2014
  • Box: Big(ger) in Japan

    Paying the piper Big(ger) in Japan Drug prices in Japan are subject to mandatory reductions after launch, but there is an opportunity for companies to receive a premium, as well as for the price to be increased …

    Published on 9/1/2014
  • Box: Capping Orphans

    Paying the piper Capping Orphans Academics at Duke University have proposed a "grant-and-access" model for ultra-Orphan drugs based on the premise that high R&D costs are limiting investment in these rarest of …

    Published on 9/1/2014
  • Box: Code conundrum

    Paying the piper Code conundrum The U.S. drug coding system presents a challenge for companies that want to try flat pricing schemes. Once a drug is approved in the U.S., CMS establishes a code that connects the …

    Published on 9/1/2014
  • Box: Financing cures

    Paying the piper Financing cures Tanisha Carino of Avalere Health LLC and Scott Gottlieb of the American Enterprise Institute (AEI) both acknowledge that current pricing and reimbursement models are not structured …

    Published on 9/1/2014
  • Box: Pricing Cerdelga

    Paying the piper Pricing Cerdelga Finding U.S. Medicaid pricing regulations too limiting for a bolder experiment just yet, Genzyme Corp. is adopting a version of portfolio pricing lite for two Gaucher's drugs with …

    Published on 9/1/2014

< Previous   1  2  3  4  5  6  7  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993